Enhanced degradation of dihydrofolate reductase through inhibition of NAD kinase by nicotinamide analogs

Molecular Pharmacology

Volumn 83, Issue 2, 2013, Pages 339-353

  Hsieh, Yi Ching ^a   Tedeschi, Philip ^a   Lawal, Rialnat AdeBisi ^a   Banerjee, Debabrata ^a   Scotto, Kathleen ^a   Kerrigan, John E ^a   Lee, Kuo Chieh ^a   Johnson Farley, Nadine ^a   Bertino, Joseph R ^a   Abali, Emine Ercikan ^b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; METHOTREXATE; NICOTINAMIDE ADENINE DINUCLEOTIDE KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NICOTINAMIDE DERIVATIVE; THIONICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER INHIBITION; COLON CANCER; CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; HALF-LIFE; HUMANS; METHOTREXATE; NADP; NIACINAMIDE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROTEOLYSIS; TETRAHYDROFOLATE DEHYDROGENASE; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84872694403     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.080218     Document Type: Article

References (62)

1. Abali EE, Skacel NE, Celikkaya H, and Hsieh YC (2008) Regulation of human dihydrofolate reductase activity and expression. Vitam Horm 79:267-292.
2. Ainavarapu SR, Li L, Badilla CL, and Fernandez JM (2005) Ligand binding modulates the mechanical stability of dihydrofolate reductase. Biophys J 89:3337-3344.
3. Alt FW, Kellems RE, Bertino JR, and Schimke RT (1978) Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J Biol Chem 253:1357-1370.
4. Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R, and Bertino JR (2002) Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta 1587:164-173.
5. Berendsen HJC, Postma JPM, vanGunsteren WF, DiNola A, and Haak JR (1984) Molecular dynamics with coupling to an external bath. J Chem Phys 81:3684-3690.
6. Bogan KL and Brenner C (2008) Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD1 precursor vitamins in human nutrition. Annu Rev Nutr 28:115-130.
7. Case DA, Cheatham TE, 3rd, Darden T, Gohlke H, Luo R, Merz KM, Jr, Onufriev A, Simmerling C, Wang B, and Woods RJ (2005) The Amber biomolecular simulation programs. J Comput Chem 26:1668-1688.
8. Chattopadhyay S, Moran RG, and Goldman ID (2007) Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 6: 404-417.
9. Cheok MH and Evans WE (2006) Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer 6:117-129.
10. Chou TC and Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
11. Chu E, Takimoto CH, Voeller D, Grem JL, and Allegra CJ (1993) Specific binding of human dihydrofolate reductase protein to dihydrofolate reductase messenger RNA in vitro. Biochemistry 32:4756-4760.
12. Darden T, York D, and Pedersen L (1993) Particle Mesh Ewald: An N-log(N) method for Ewald sums in large systems. J Chem Phys 98:10089-10092.
13. Dunn SM, Batchelor JG, and King RW (1978) Kinetics of ligand binding to dihydrofolate reductase: binary complex formation with NADPH and coenzyme analogues. Biochemistry 17:2356-2364.
14. Ercikan-Abali EA, Banerjee D, Waltham MC, Skacel N, Scotto KW, and Bertino JR (1997) Dihydrofolate reductase protein inhibits its own translation by binding to dihydrofolate reductase mRNA sequences within the coding region. Biochemistry 36:12317-12322.
15. Ercikan-Abali EA, Mineishi S, Tong Y, Nakahara S, Waltham MC, Banerjee D, Chen W, Sadelain M, and Bertino JR (1996) Active site-directed double mutants of dihydrofolate reductase. Cancer Res 56:4142-4145.
16. Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, and Pedersen L (1995) A smooth particle mesh ewald method. J Chem Phys 103:8577-8592.
17. Estrela JM, Ortega A, and Obrador E (2006) Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci 43:143-181.
18. Ghoshal K, Datta J, Majumder S, Bai S, Kutay H, Motiwala T, and Jacob ST (2005) 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol 25:4727-4741.
19. Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D, and Bertino JR (1996) Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 335:1041-1048.
20. Hawkins GD, Cramer CJ, and Truhlar DG (1995) Pairwise solute descreening of solute charges from a dielectric medium. Chem Phys Lett 246:122-129.
21. Hawkins GD, Cramer CJ, and Truhlar DG (1996) Parametrized models of aqueous free energies of solvation based on pairwise descreening of solute atomic charges from a dielectric medium. J Phys Chem 100:19824-19839.
22. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, and Simmerling C (2006) Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 65:712-725.
23. Hou T, Wang J, Li Y, and Wang W (2011) Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. J Chem Inf Model 51:69-82.
24. Hsieh YC, Skacel NE, Bansal N, Scotto KW, Banerjee D, Bertino JR, and Abali EE (2009) Species-specific differences in translational regulation of dihydrofolate re-ductase. Mol Pharmacol 76:723-733.
25. Humphrey W, Dalke A, and Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14:33-38, 27-28.
26. Johnston JA, Johnson ES, Waller PR, and Varshavsky A (1995) Methotrexate inhibits proteolysis of dihydrofolate reductase by the N-end rule pathway. J Biol Chem 270:8172-8178.
27. Latif S, Bauer-Sardina I, Ranade K, Livak KJ, and Kwok PY (2001) Fluorescence polarization in homogeneous nucleic acid analysis II: 59-nuclease assay. Genome Res 11:436-440.
28. Lerner F, Niere M, Ludwig A, and Ziegler M (2001) Structural and functional characterization of human NAD kinase. Biochem Biophys Res Commun 288:69-74.
29. Liu J, Lou Y, Yokota H, Adams PD, Kim R, and Kim SH (2005) Crystal structures of an NAD kinase from Archaeoglobus fulgidus in complex with ATP, NAD, or NADP. J Mol Biol 354:289-303.
30. Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
31. Malek K, Boosalis MS, Waraska K, Mitchell BS, and Wright DG (2004) Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I. In vivo studies. Leuk Res 28:1125-1136.
32. McTigue MA, Davies JF, 2nd, Kaufman BT, and Kraut J (1993) Crystal structures of chicken liver dihydrofolate reductase: binary thioNADP1 and ternary thioNADP1. biopterin complexes. Biochemistry 32:6855-6862.
33. Meng EC, Pettersen EF, Couch GS, Huang CC, and Ferrin TE (2006) Tools for integrated sequence-structure analysis with UCSF Chimera. BMC Bioinformatics 7:339.
34. Mini E, Moroson BA, Franco CT, and Bertino JR (1985) Cytotoxic effects of folate antagonists against methotrexate-resistant human leukemic lymphoblast CCRF-CEM cell lines. Cancer Res 45:325-330.
35. Miyata Y (2005) Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents. Curr Pharm Des 11:1131-1138.
36. Nakano T, Spencer HT, Appleman JR, and Blakley RL (1994) Critical role of phe-nylalanine 34 of human dihydrofolate reductase in substrate and inhibitor binding and in catalysis. Biochemistry 33:9945-9952.
37. Noé V, MacKenzie S, and Ciudad CJ (2003) An intron is required for dihydrofolate reductase protein stability. J Biol Chem 278:38292-38300.
38. O'Reilly T and Niven DF (2003) Levels of nicotinamide adenine dinucleotide in extracellular body fluids of pigs may be growth-limiting for Actinobacillus pleuro-pneumoniae and Haemophilus parasuis. Can J Vet Res 67:229-231.
39. Onufriev A, Bashford D, and Case DA (2000) Modification of the generalized Born model suitable for macromolecules. J Phys Chem B 104:3712-3720.
40. Onufriev A, Bashford D, and Case DA (2004) Exploring protein native states and large-scale conformational changes with a modified generalized born model. Proteins 55:383-394.
41. Perkins JP, Hillcoat BL, and Bertino JR (1967) Dihydrofolate reductase from a resistant subline of the L1210 lymphoma. Purification and properties. J Biol Chem 242:4771-4776.
42. Pollak N, Niere M, and Ziegler M (2007) NAD kinase levels control the NADPH concentration in human cells. J Biol Chem 282:33562-33571.
43. Rego-Pérez I, Fernández-Moreno M, and Blanco FJ (2008) Gene polymorphisms and pharmacogenetics in rheumatoid arthritis. Curr Genomics 9:381-393.
44. Roberts E, Eargle J, Wright D, and Luthey-Schulten Z (2006) MultiSeq: unifying sequence and structure data for evolutionary analysis. BMC Bioinformatics 7:382.
45. Roussel B, Johnson-Farley N, Kerrigan JE, Scotto KW, Banerjee D, Felczak K, Pankiewicz KW, Gounder M, Lin HX, and Abali EE et al. (2012) A second target of benzamide riboside: Dihydrofolate reductase. Cancer Biol Ther 13:1290-1298.
46. Russell RB and Barton GJ (1992) Multiple protein sequence alignment from tertiary structure comparison: assignment of global and residue confidence levels. Proteins 14:309-323.
47. Salvador N, Aguado C, Horst M, and Knecht E (2000) Import of a cytosolic protein into lysosomes by chaperone-mediated autophagy depends on its folding state. J Biol Chem 275:27447-27456.
48. Skacel N, Menon LG, Mishra PJ, Peters R, Banerjee D, Bertino JR, and Abali EE (2005) Identification of amino acids required for the functional up-regulation of human dihydrofolate reductase protein in response to antifolate Treatment. J Biol Chem 280:22721-22731.
49. Slack JL, Bi W, Livak KJ, Beaubier N, Yu M, Clark M, Kim SH, Gallagher RE, and Willman CL (2001) Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARalpha mRNA using real-time reverse-transcription polymerase chain reaction. J Mol Diagn 3:141-149.
50. Slansky JE and Farnham PJ (1996) Transcriptional regulation of the dihydrofolate reductase gene. Bioessays 18:55-62.
51. Smith SL and Burchall JJ (1983) Alpha-pyridine nucleotides as substrates for a plasmid-specified dihydrofolate reductase. Proc Natl Acad Sci USA 80: 4619-4623.
52. Sowers R, Toguchida J, Qin J, Meyers PA, Healey JH, Huvos A, Banerjee D, Bertino JR, and Gorlick R (2003) mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma. Mol Cancer Ther 2:535-541.
53. Tai N, Schmitz JC, Chen TM, and Chu E (2004a) Characterization of a cis-acting regulatory element in the protein-coding region of human dihydrofolate reductase mRNA. Biochem J 378:999-1006.
54. Tai N, Schmitz JC, Liu J, Lin X, Bailly M, Chen TM, and Chu E (2004b) Trans-lational autoregulation of thymidylate synthase and dihydrofolate reductase. Front Biosci 9:2521-2526.
55. Thillet J, Adams JA, and Benkovic SJ (1990) The kinetic mechanism of wild-type and mutant mouse dihydrofolate reductases. Biochemistry 29:5195-5202.
56. Tong X, Zhao F, and Thompson CB (2009) The molecular determinants of de novo nucleotide biosynthesis in cancer cells. Curr Opin Genet Dev 19:32-37.
57. Vander Heiden MG, Cantley LC, and Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029-1033.
58. Wallace LA and Robert Matthews C (2002) Highly divergent dihydrofolate reduc-tases conserve complex folding mechanisms. J Mol Biol 315:193-211.
59. Wang H, Tempei W, Wernimont AK, Tong Y, Guan X, Shen Y, Li Y, Arrowsmith CH, Edwards AM, Bountra C et al.(2010) Crystal structure of human NAD kinase, in RCSB PDB, 3PFN. DOI: 10.2210/pdb3pfn/pdb.
60. Wang J, Wang W, Kollman PA, and Case DA (2006) Antechamber, an accessory software package for molecular mechanics calculations. J Mol Graphics Model 25: 247-260.
61. Wang K, Ma Q, Ren Y, He J, Zhang Y, Zhang Y, and Chen W (2007) Geldanamycin destabilizes HER2 tyrosine kinase and suppresses Wnt/beta-catenin signaling in HER2 overexpressing human breast cancer cells. Oncol Rep 17:89-96.
62. Xiang J (2002) JACKAL: A Protein Structure Modeling Package, Columbia University, New York, NY.